Vielight Photobiomodulation Study Eligibility Survey (Device Loans for ME/CFS and Long COVID)
SIGNAL team <
signal@renegade-research.org> To: <xxxxx>
Thu, Nov 19 at 1:36 PM
Hi xxxxxxx,
Snapshot
Eligibility survey for Vielight trial here! Due by Dec 11, 2026
Before starting survey please complete a FUNCAP assessment-free link MoCA XpressO cognitive screening-instructions
Study details, requirements, possible risk/benefit information below
In case you missed it. Solve ME webinar on SIGNAL
Our first Vielight study has been been officially approved by IRB (Institutional Review Board)! Thank you so much for your patiencein this process.
Watch the Solve ME webinar on SIGNAL to learn more about how we got started, the science behind the first two devices (Vielight photobiomodulation device and Truvaga vagus nerve stimulation), some details of the Vielight project, and a look forward for what we
plan over the next year.
ELIGIBILITY SURVEY
The eligibility survey for Vielight study is here! Before starting the survey, please complete the MoCA XpressO & FUNCAP below.
Please complete by Friday, December 11, 2026:
1. The MoCA XpressO cognitive screening Must be completed by prospective participant Click for detailed instructions
2. A recent FUNCAP score
A recent FUNCAP can be used from any platform.
Here is a free website to determine your score
May be completed by prospective participant with assistance from caregiver
3. Basic Eligibility survey (link)
The first several pages are consent documents to gather information
To minimize PEM you may complete each part on separate daysIf you are eligible after completing these steps, you will be invited to complete informed consent and enroll in this study.
Enrollment for the first Vielight study is expected to begin December 2026 and will enroll 40 participants
Study estimated to start in January 2026
If you are not eligible at this time, please be assured we will have more studies in the future.
STUDY DETAILS
The purpose of this research study is to test the effectiveness of Vielight Gamma in improving cognitive performance and cognitive functional capacity in people with ME
To be eligible for this study you must:
Be 18-65 years of age
Live in the USA & be fluent in English
Have ME/CFS prior to 2020 (not from Long Covid)
Experience Brain fog/possible Mild Cognitive Impairment determined by MoCA XpressO
Have Moderate to Very Severe ME determined by FUNCAP
Participation Requirements: Smart phone, tablet, laptop, or computer and able to use screen up to 15 minutes
Device use per titration protocol (up to 20min 6x week) ~10 weeks
Complete short daily survey (~2 minutes) ~10 weeks
Complete assessments every other/weekly (~5-15min) for ~10 weeks plus 4 weeks follow up after stopping device
Follow up surveys at 4 weeks
Return device after testing period
Compensation:
There is no cost to participants. Vielight Gamma device and return shipping will be provided
Participants will receive $0 in monetary compensation.
Possible benefits:
Cognitive impairment and cognitive functional capacity may improve as part of the study, but can not be guaranteed. However, this study may help people in the future.
Possible risks:
The ME/CFS population is known to have new and heightened sensitivities. Dose scale has been modified to titrate dose up to recommended levels for cognitive impairment by manufacturer.
Temporary symptoms of too high dosage:
HeadachePEM (particularly cognitive)
Thank you,
ME Vielight Study Team